. 2024 Aug 20;37:13220. doi: 10.3389/ti.2024.13220
Copyright © 2024 Re Sartò, Alfieri, Cosmai, Brigati, Campise, Regalia, Verdesca, Molinari, Pisacreta, Pirovano, Nardelli, Gallieni and Castellano.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
FIGURE 2.
Competing risk analysis: Basiliximab and ATG in relation to time to cancer diagnosis post-KTx.